The end of the antibiotic era
For eighty years antibiotics made bacterial infection a footnote. That era is closing. Resistance is rising faster than the pipeline can replace it, and the math of the coming decades is stark. Phage cocktails are one of the few fundamentally new weapons on the table — and that is what turns a public-health emergency into a generational industry.
The measured toll
Not a forecast — a body count that is already here
The headline “10 million by 2050” is a projection, and we label it as one. But the present tense is not modeled — it is counted. In 2019, bacterial AMR was directly responsible for roughly 1.27 million deaths and associated with nearly 5 million. The trajectory from there compounds for decades.
Projections from the O’Neill Review are scenario models; the 2019 and forecast figures are from the Lancet GRAM studies. Full citations on the references page.
The broken market
Why antibiotics stopped being invented
The cruelty of AMR economics: a successful new antibiotic is one we save for emergencies and use as little as possible. That makes it a terrible product and a great public good — so pharma has largely walked away. Several antibiotic startups that did win approval went bankrupt anyway. Governments are still debating “pull incentives” (the PASTEUR Act has been reintroduced repeatedly without passing).
Phage cocktails sidestep part of this trap. They are re-matchable — when resistance emerges you swap a phage rather than spend a decade on a new molecule — and they open new indications (biofilms, decolonization, microbiome editing) where no antibiotic competes. That combination is what makes the category investable.
The opportunity
The “trillion-dollar” claim, kept honest
It is tempting to call phage therapy a trillion-dollar market. The disciplined version is more persuasive: the trillions are the cost of the problem, not the current size of the solution. AMR is projected to cost up to $100 trillion in cumulative global output by 2050. That is the addressable pain. The phage market today is a rounding error against it — which is exactly the point for anyone building early.
Estimates of the phage-therapy market vary more than fifteen-fold between research firms — from under $100 million to over $1.4 billion for roughly the same year — because no one agrees on what counts. We cite the range rather than a single flattering number. The signal that matters is structural: a ~$53-billion global antibiotics market, a multi-trillion-dollar cost of failure, and zero approved phage drugs standing in the gap.
The path to value is not “replace all antibiotics.” It is to own the indications antibiotics can’t serve, to become the standard adjuvant that rescues them, and — eventually — to build the manufacturing and personalization infrastructure that makes precision antibacterials routine.
“The question is no longer whether the antibiotic era ends. It is what replaces it — and whether we build that replacement before, or after, the deaths arrive on schedule.”